Overview

Gender

male

Investor Type

Investment Partner

Josh Bilenker serves as a Partner of Aisling Capital. Previously, Josh Bilenker was a Medical Officer in the Office of Oncology Drug Products at the U.S. Food and Drug Administration. While at the FDA, he conducted clinical reviews of IND-stage and licensed biologic oncology products. Prior to joining the FDA, Josh Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties.

Josh Bilenker currently serves as a director of LensAR, Inc., Roka Bioscience, Inc., T2 Biosystems and ViewRay, Inc and as a board observer at Aragon Pharmaceuticals. He is also a Board Member of the NCCN Foundation and of BioEnterprise. Josh Joshua H. Bilenker, M.D., founder of Loxo Oncology, serves as President and Chief Executive Officer, and sits on the board of directors.Previously, Josh Bilenker was a Partner at Aisling Capital, a multi-strategy healthcare investment firm based in NY, where he remains a Venture Partner.

From 2004-2006, Josh Bilenker was a Medical Officer at the U.S. FDA in the Office of Oncology. Josh Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties.

Josh Bilenker received his M.D. from The Johns Hopkins School of Medicine. He received his A.B. from Princeton, awarded summa cum laude in English.